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Abstract
Background: As information on incidence, risk factors, and outcome of acute leukemia (AL) relapse after unmanipulated
haploidentical stem cell transplantation (haplo-SCT) is scarce, a retrospective registry study was performed by the Acute
Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Methods: Among 1652 transplants performed for lymphoblastic and myeloid AL between 2007 and 2014, 587 patients
(acute lymphoblastic leukemia (ALL) 131, acute myeloid leukemia (AML) 456) with detailed information were analyzed
aiming to identify risk factors for post-transplant relapse and for overall survival (OS) after relapse.
Results: The cumulative incidence of relapse at 3 years was 44% (35–53%) for ALL and 32% (27–36%) for AML (p = 0.023).
In ALL, risk factors for relapse were disease status different from the first complete remission (CR1) at haplo-SCT (CR2 vs
CR1: HR 2.85, p = 0.011; advanced vs CR1: HR 14.28, p < 0.0001) and male donor gender (HR 3.64, p = 0.0002), while in
AML, risk factors were advanced disease at haplo-SCT (advanced vs CR1: HR 3.95, p < 0.0001) and comorbidities (HCT-CI)
≥ 3 (HR 1.75, p = 0.014). Transplants performed in more recent years were associated with lower relapse incidence (RI) in
AML, but not in ALL (HR 0.91, p = 0.042). After relapse, median follow-up was 13months (mos). OS at 1-year post relapse
was 18%. Prognostic factors for superior OS after relapse were remission at time of haplo-SCT (CR vs advanced: HR 0.71,
p = 0.028), time from transplant to relapse (≥ 5 mos vs < 5 mos: HR 0.530, p < 0.0001), and bone marrow as a stem cell
source (peripheral blood (PB) vs bone marrow (BM): HR 1.473, p = 0.016).
Conclusions: Risk factors for relapse after haploidentical transplantation were disease specific. Longer OS after relapse was
achieved in particular by patients both in CR at haplo-SCT and relapsing more than 5 months after transplant
(1-year OS 33%).
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Introduction
Allogeneic stem cell transplantation (allo-SCT) repre-
sents a curative option for intermediate- and high-risk
adult acute leukemias (AL). In the absence of a matched
donor, haploidentical donors are increasingly used with
favorable outcomes [1–5]. Despite substantial improve-
ments in non-relapse mortality (NRM) over the years,
relapse of acute leukemia remains the leading cause of
failure after allo-SCT. Following haploidentical trans-
plant (haplo-SCT), relapse incidence (RI) ranges from 22
to 30% [6–9] up to 58% when reduced intensity condi-
tioning (RIC) regimens are used [10].
In the haplo-SCT setting, major human leukocyte antigen
(HLA) mismatches between donor cells and recipient
leukemic cells may theoretically serve as potential targets
for a strong allogeneic graft vs leukemia (GVL) effect.
Nevertheless, recent studies from the Acute Leukemia
Working Party (ALWP) of the European Society for Blood
and Marrow Transplantation (EBMT) could only show a
trend for a lower RI among patients with high-risk acute
myeloid leukemia after haplo-SCT in comparison to identi-
cal sibling transplants [11, 12].
Several single-center-based studies have reported risk
factors [13–15] and treatment of leukemia relapse after
haplo-SCT [16–19]. Nevertheless, a systematic analysis
aiming at identifying risk factors and timing of relapse,
and describing possible treatments of leukemia relapse
after haplo-SCT is still lacking. For these reasons, we de-
cided to perform a large, registry-based study, using the
EBMT-ALWP registry to identify risk factors and asses-
sing outcome of leukemic relapse after haplo-SCT.
Patients and methods
Inclusion criteria of the study were as follows: age ≥ 18
years; diagnosis of either acute myeloid (AML) or acute
lymphoblasic leukemia (ALL) both de novo and second-
ary; non-ex vivo T cell-depleted SCT from a family
donor with ≥ 2 HLA mismatches between donor and re-
cipient; peripheral blood (PB) or bone marrow (BM) as
source of SC; first allo-SCT (previous autologous SCT
was allowed), regardless of stage at SCT. All patients
underwent transplantation between January 2007 and
December 2014.
Data for this retrospective multicenter analysis were
provided and approved by the ALWP of the EBMT
registry. The EBMT is a non-profit, scientific society
representing more than 600 transplant centers mainly in
Europe. The EBMT promotes all activity aiming to im-
prove stem cell transplantation or cellular therapy,
which includes registering all the activity relating to
stem cell transplants. Data are entered, managed, and
maintained in a central database with internet access;
each EBMT center is represented in this database. There
are no restrictions on centers for reporting data, except
for those required by the law on patient consent, data
confidentiality, and accuracy. Quality control measures
included several independent systems: confirmation of
validity of the entered data by the reporting team, se-
lective comparison of the survey data with minimum
essential data A (MED-A) data sets in the EBMT
registry database, cross-checking with the National
Registries, and regular in-house and external data au-
dits. Since 1990, patients have provided informed
consent authorizing the use of their personal informa-
tion for research purposes.
Definitions and statistical analysis
Primary endpoints were [1] incidence and risk factors
of leukemia relapse after transplant and [2] risk factors
for overall survival (OS) after relapse. RI after transplant
was defined as time from date of transplant to leukemia
relapse. NRM was defined as death without evidence of
relapse. Death without hematological relapse and relapse
were competitive risks for relapse incidence (RI) and
NRM, respectively. OS after relapse was defined as time
from date of relapse and death from all causes. Acute
GVHD was graded according to the modified Seattle
Glucksberg criteria [20], and cGVHD according to the
revised Seattle criteria [21].
Myeloablative conditioning regimens (MAC) were de-
fined as including total body irradiation (TBI) > 8 Gy, or
busulfan > 8mg/kg, or more than one alkylating agent
as per EBMT criteria [22].
The patient’s comorbidities were classified using the
hematopoietic stem cell transplantation-specific comor-
bidity index (HCT-CI) according to Sorror et al [23].
The type I error rate was fixed at 0.05 for determin-
ation of factors associated with time to event. Multivari-
ate analyses were performed using Cox regression
models and stepwise regression procedures. Analyses
were performed using the R statistical software version
3.2.3 (R Development Core Team, Vienna, Austria).
As ALL and AML differ in biology, risk classification,
induction treatment, and outcomes including relapse
rates [6, 24], and also because of significant differences
in patients’ characteristics (Table 1), we analyzed these
two populations separately.
Results
Patients’ and donors’ characteristics and overall outcome
Between January 2007 and December 2014, 1652 adult
patients received a Haplo-SCT for acute leukemia. In
587 out of 1652 haplo-SCT (35%), detailed information
on the characteristics of disease and management of re-
lapse was provided by the respective transplant centers,
allowing for the analysis of incidence and risk factors of
leukemia relapse after transplant (RI) and overall sur-
vival (OS) after relapse. This group was well matched to
the entire cohort of 1652 patients with respect to sex of
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patients, year of transplantation, source of stem cells,
and diagnosis. In contrast, the patients reported more in
detail were older, had been transplanted more frequently
in advanced stage, and had been given more post-
transplant cyclophosphamide (PT-Cy) for GVHD
prophylaxis (Additional file 1: Table S1). Nevertheless,
relapse incidence did not differ between the two groups
(Fig. 1a), which is why we considered the cohort of pa-
tients reported more in detail as a representative.
Patients’ and disease characteristics of the 587 patients
with detailed information are described in Table 1. Pa-
tients’ median age was 37 (18–76) years for ALL and 48
(18–78) years for AML (p < 0.0001). Conditioning regi-
mens, graft vs host disease (GvHD) prophylaxis, and
stem cell source are described in Table 2. Myeloablative
conditioning regimens were mostly employed in ALL
(92 patients, 70.23%) than in AML (221 patients,
48.46%) (p < 0.001). No statistical differences were found
in means of in vivo T cell depletion (PT-Cy vs antithy-
mocyte globulin (ATG)) or source of stem cells (PB vs
BM) between the ALL and AML groups. ATG was used
for in vivo T cell depletion in 46 patients with ALL
(35.11%) and 169 with AML (37.06%) while post-
transplant cyclophosphamide (PT-Cy) was applied in 85
ALL (64.89%) and 87 AML (62.94%) patients, respect-
ively (p = 0.76). Peripheral blood stem cells were the
stem cell source in 81 ALL (61.83%) and 253 AML
(55.48%) patients, respectively (p = 0.233).
Relapse incidence after haplo-SCT
Relapse occurred in 197 out of 587 patients, 54 ALL
(27%) and 143 AML (73%). Characteristics of relapsed
Table 1. Patients’, donors’, and disease characteristics
SCT stem cell transplant, CT chemotherapy, HCT-CT hematopoietic cell transplantation comorbidity index, CR complete remission, AML acute myeloid leukemia,
Ph + ALL Philadelphia positive chromosome acute lympholastic leukemia, NA not applicable
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patients are described in Additional file 2: Table S2. The
CI of relapse at 3 years was 44% (35–53%) for ALL and
32% (27–36%) for AML (p = 0.023) (Fig. 1b).
Results for univariate analysis of risk factors for RI
are shown in Additional file 3: Table S3. Among ALL
patients, multivariate analysis revealed a lower RI after
allo-SCT performed in CR1 (CR1 22%, CR2 48%, p <
0.001; CR ≥ 2 vs CR1: HR 2.98, p = 0.0087; not CR vs
CR1: HR 14.83, p < 0.0001). Among ALL patients with
advanced disease at transplantation, all but one
experienced relapse. In addition, male donors were as-
sociated with higher RI (male vs female: HR 3.64, p =
0.0002). Risk factors for a higher RI AML were disease
status at transplant other than CR (not CR vs CR1: HR
3.95, p < 0.0001), year of transplant (1-year increase:
HR 0.91, p = 0.0425), and HCT-CI ≥ 3 (HCT-C ≥ 3 vs
0: HR 1.75, p = 0.0143) (Table 3).
Characteristics and treatment of leukemia relapse post
haplo-SCT
Median time from transplant to relapse was 4.91months
(0.03–62.77). Twenty-nine out of 197 (14%) relapsed pa-
tients experienced extramedullary relapse (EMR), 14 (26%)
among ALL patients and 15 (10%) among patients with
AML. EMR showed a trend for a later onset after transplant
than hematological relapse (6.1 vs 4.9months) (p = 0.08).
Treatment of relapse varied and included withdrawal
of immunosuppression, chemotherapy, tyrosine kinase
inhibitors (TKI), donor lymphocyte infusion (DLI), and a
second allo-SCT (Table 4). Strategies were used either
alone or in combination.
Outcome and risk factors for survival after relapse
Median follow-up from date of relapse to last contact
was 13months. OS was 18% and 8% at 1 and 2-year post
relapse, respectively. Leukemia was by far the leading
a
b
Fig. 1 a Incidence of relapse in the 587 patients included in our analysis and the 1065 patients transplanted in the same years in the EBMT
centers but not included in the final analysis due to incomplete data. b Incidence of relapse in patients with ALL and AML included in our analysis
Piemontese et al. Journal of Hematology & Oncology           (2019) 12:68 Page 4 of 11
cause of death (154 patients, 90%), followed by infec-
tions (13 patients, 7.4%). Two patients died from GvHD
(1.1 %), while 3 (1.5%) from other transplant-related
causes.
The 1-year overall survival after relapse was higher for
patients transplanted in remission (29% CR1, 25% CR ≥
2, 10% not in remission, p = 0.023), for those with good/
intermediate cytogenetic (25% good/intermediate vs 9%
Table 2. Conditioning regimen for haplo-SCT
TBF thiotepa–busulfan–fludarabine, TREO treosulfan, FLU fludarabine, TBI total body irradiation, Cy cyclophosphamide, BU busulfan, MEL melphalan, THIO thiotepa,
PT-Cy post-transplant cyclophosphamide, FK506 tacrolimus, MMF micophenolate mofetil, Rapa rapamycin, ATG antithymocyte globulin, CSA cyclosporine
*Sequential regimen of chemotherapy
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in those with poor/NA, p = 0.004), for patients who re-
lapsed more than 5months after haplo-SCT (26% > 5
months vs those who relapsed ≤ 5 months (10%, p >
0.0001)), in patients having received bone marrow grafts
(26% BM, 11% PB, p = 0.006), and for patients without
grade II–IV aGvHD (21% no, 6% yes, p = 0.09). The
prognostic factors for higher OS confirmed by multivari-
ate analysis were remission at time of haplo-SCT, time
from transplant to relapse (> 5 months), and stem cell
source (BM) (Table 5 and Fig. 2a–c). In 49 out of 197
patients (33%) that showed both remission at time of
haplo-SCT and relapse > 5 months from transplantation,
the 1- and 2-year OS were 33% and 14%, respectively
(p = 0.003).
Since the reason why patients have been assigned to
the different treatments could not be evaluated retro-
spectively, no comparison among different strategies
could be performed. Second allo-SCT was performed in
29 relapsing patients; out of them, 9 were in CR (≥ 2,
31%), while 20 were in relapse (69%) at the time of sec-
ond haplo-SCT. The 1- and 2-year OS following the
second allo-SCT were 25% (13–48%) and 12% (4–35%),
respectively. Only 3 patients are alive at 6, 29, and 61
months from second allo-SCT.
Discussion
Leukemia relapse is the leading cause of failure after
allo-SCT including in transplants from haploidentical
donors [1–5, 24]. Most studies comparing haploidentical
donors to matched unrelated or related donors did not
find any overall differences in terms of leukemia relapse
according to donor type [6, 11, 12, 25, 26]. In contrast,
Ciurea et al. compared haplo-SCT to transplants from
unrelated donors in AML and described a higher inci-
dence of relapse after haplo-SCT after RIC regimens
[10], whereas Luo et al. reported a lower incidence of re-
lapse in patients with hematological malignancies under-
going haploidentical versus matched sibling donor SCT
in a setting of ATG-based immunosuppression [27].
The current report represents a large registry-study fo-
cusing on relapse after haplo-SCT for acute leukemia
analyzing risk factors, timing, treatment strategies, and
Table 3. Multivariate analysis for relapse incidence after haplo-SCT for ALL and AML
ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, RI relapse incidence, HR hazard ratio, SCT stem cell transplant, CR complete remission, HCT-CI
hematopoietic cell transplantation comorbidity index, CMV cytomegalovirus
Table 4. Treatment of relapse after haplo-SCT
ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, SCT stem cell transplant, TKI tyrosine kinase inhibitors, DLI donor lymphocyte infusion
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overall survival after relapse. In ALL, patients trans-
planted beyond CR1 had a higher RI after haplo-SCT.
This finding is in line with extensive previous published
literature [28–30] and confirm the importance of pro-
ceeding to transplant as soon as the patients is in CR1
for those patients with an indication for allo-SCT.
As part of registry-based study limitations, we were
not able to study the impact of pre-transplant measur-
able residual disease on ALL relapse. Acute lympho-
blastic leukemia immunophenotype was available only
for a quarter of the patients so we could not analyze re-
lapse incidence between B cell and T cell ALL. Never-
theless, in a previous publication from ALWP, Santoro
et al. did not find any difference in haplo-SCT outcome
between B-ALL and T-ALL [31].
Another risk factor for ALL relapse was donor gender;
in particular, male donors were associated with a higher
RI. As male donors were associated with a lower inci-
dence of grade II–IV acute GvHD (aGvHD, Additional
file 4: Table S4), one possible reason for the higher inci-
dence of relapse could be a lower GVL effect. Recently,
McCurdy et al. described a higher PFS after PT-Cy
Haplo-SCT if grade II aGvHD had occurred [32].
Nakasone et al. [33] have previously reported lower inci-
dence of relapse in a subset of male patients receiving
allo-SCT from a female donor. Baron et al. [34] also re-
ported a reduced incidence of acute leukemia relapse and
a higher incidence of cGvHD in the combination of female
donors to male patients. Of note, in our study, male do-
nors were also a risk factor for a lower leukemia-free sur-
vival (LFS) and OS but not for higher NRM both in ALL
and in AML.
Not unexpectedly, also in AML, disease status at
transplant was a risk factor for higher relapse. In
addition, patients with a HCT-CI ≥ 3 and transplanted
in older age had a higher incidence of relapse. These
findings might be explained by a lower conditioning in-
tensity in elderly patients and those transplanted earlier
or with higher comorbidities. However, the importance
of the intensity of the conditioning regimens in prevent-
ing leukemia relapse after allo-SCT is debated. Rubio et
al. had recently reported on behalf of the ALWP of the
EBMT a trend for a higher incidence of relapse in pa-
tients with AML receiving a haplo-SCT with RIC regi-
men [35]. Ciurea et al. showed a similar 1-year incidence
of relapse in AML patients after haplo-SCT using RIC
and MAC regimens [10]. In our current study, the inten-
sity of conditioning regimen did not affect RI neither in
ALL nor in AML. Of note, RIC regimens were associ-
ated to a lower incidence of aGvHD II–IV in ALL and
lower NRM in AML without affecting OS and LFS
(Additional file 4: Table S4). Importantly, according to
our data (Table 3), incidence of AML relapse post haplo-
SCT is decreasing in transplants performed in more re-
cent years. This might be in part due to modern ap-
proaches for the prevention of post-transplant relapse,
including prophylactic or pre-emptive strategies such as
hypomethylating agents, DLI, and anti-FLT3 inhibitors
[36–39], although not enough data were available in the
registry to study this aspect in detail.
Concerning stem cell source, Bashey et al. [40] have
recently reported a lower incidence of relapse after
haplo-SCT for acute leukemia using PBSC. In contrast,
in our analysis, stem cell source did not affect RI neither
in ALL nor in AML. Furthermore, bone marrow grafts
were associated with a lower incidence of cGvHD in
ALL patients without affecting OS, LFS, aGVHD, and
NRM (Additional file 4: Table S4). Our current data
are consistent with previous publication showing
comparable results for PBSC or BM recipients in
haplo-SCT [41].
Incidence of extramedullary relapse (EMR) was higher
in our cohort comparing to previous reports (14% vs 4–
10%). A possible explanation could be the higher num-
ber of ALL patients in active disease at time of trans-
plant, a well-known factor associated with EMR [42–45].
In agreement with previously published literature, EMR
relapses occurred later than hematological relapses [45]
(6.1 vs 4.91 months), even if it was only a trend in our
data. The exact cause of late transplant-failure at extra-
medullary sites is unclear but may result from the devel-
opment of immune tolerance at peripheral sites (which
Table 5. Multivariate analysis of risk factors for OS after relapse
OS overall survival, HR hazard ratio, CI confidence interval, CR complete remission, PB peripheral blood, BM bone marrow
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are also shielded to a degree from chemotherapy and
conditioning regimens) [46, 47].
It is well established that patients with acute
leukemia relapsing after a first allograft have a poor
prognosis with a survival of only few months [48, 49].
Chemotherapy-based re-induction may result in re-
mission rates of up to 70%, but OS rarely exceeds
15–20% at 2 years [48, 49]. DLI can be an additional
option, but patients with relapsed leukemia rarely ex-
perience long-term benefit [50].
In the current study, various treatment modalities
were used to conquer the leukemia relapses post haplo-
SCT with a limited success rate in agreement with previ-
ous publications, regardless of donor type [36, 51-52].
Similar to the report by McCurdy et al. [26], we
observed an inverse correlation between time to relapse
post haplo-SCT and outcome, with better 1-year OS in
patients relapsing > 5months post haplo-SCT. Further,
haplo-SCT in CR was associated with improved outcome
even after post-transplant relapse. Notably, we were able
a
b
c
Fig. 2 Overall survival from relapse according to a disease status at time of haplo-SCT, b stem cell source, and c time from transplant to relapse
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to identify a subgroup of patients with a better prognosis
after relapse: Those 49 patients that were transplanted
in remission and relapsed later than 5 months after
transplant had better outcome and might be the most
appropriate candidates for aggressive treatments such as
second transplants. This approach is still intended to be
curative; however, it is usually associated with higher
toxicity and NRM [53–56].
Finally, stem cell source for the initial haplo-SCT
influenced OS after relapse. Patients that received BM
experienced a higher 1-year OS after relapse post
haplo-SCT in comparison to those transplanted with
PB (11% vs 2%). One explanation could be the
slightly higher incidence of cGvHD, which is usually
associated with GvL effects, among patients receiving
PB (Additional file 4: Table S4, also shown by Bashey
and colleagues [40]). This might indicate a kind of re-
sistance against GvL effects in those patients develop-
ing relapse.
In summary, within the limitations of a retrospective
registry study, this analysis underscores the importance
of remission of disease at time of haplo-SCT and coordi-
nated timing of transplants, aiming in both lowering re-
lapse incidence and increasing survival among those
patients who develop relapse anyway. Donor gender, pa-
tient comorbidities, and year of transplantation are add-
itional prognostic factors for leukemia relapse. Overall
survival after relapse is dismal, but we were able to iden-
tify a subgroup of patients with better prognosis, those
transplanted in complete remission and relapsing > 5
months after haplo-SCT.
If confirmed in further studies, these findings may
contribute to the early identification of patients at higher
risk of relapse after haplo-SCT. Furthermore, they can
help to overcome some of the risk factors for relapse in
the pre-transplant setting or precociously planning post-
transplant maintenance strategies. Finally, they can help
us in selecting those patients that could better benefit
from further treatments after relapse. Prospective trials
comparing the different post-relapse therapeutic strat-
egies may further help in dissecting the role of each
treatment modality (Additional file 5: Table S5).
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